Overview

An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy

Status:
Enrolling by invitation

Trial end date:
2026-08-10

Target enrollment:

Participant gender:

Summary

The main objective of this study is to evaluate the safety and tolerability of long-term treatment with casimersen or golodirsen in patients with Duchenne muscular dystrophy (DMD).

Phase:

Phase 3

Details

Lead Sponsor:

Sarepta Therapeutics
Sarepta Therapeutics, Inc.